Navigation Links
Killing drug-resistant melanoma requires combination therapy
Date:12/13/2010

cells that became resistant to one type of BRAF drug became resistant to all of them, which suggests that the cells were biochemically "rewired" in such a way that they no longer needed BRAF to form tumors.

"Cells are complex machines that work, essentially, through chains of biochemical reactions that we refer to as signaling pathways," said Jessie Villanueva, Ph.D., senior author on the study and staff scientist in the Herlyn laboratory.

"Knocking out mutant BRAF shuts a major pathway down, but if some cells can use an alternate pathway, then they can survive."

To find out which alternate pathways the drug-resistant cells use, Villanueva and her colleagues looked for signs of increased activation among proteins along the pathways BRAF uses, as well as other pathways.

Their hunt turned up two paths that worked together to aid survival. First, they found that resistant cells used a protein similar to BRAF to carry the signal down the chain. Second, they found these cells received an additional boost from the IGF-1 receptor, a protein that sits on the surface of cells and sends signals that prevent cells from being killed. The resistant cells re-route the signal around BRAF by switching to an alternate protein (CRAF or ARAF), which promotes tumor cell growth, while IGF-1R signaling promotes survival of the resistant cells.

Fortunately, there are a number compounds in clinical development that could block signals along both these pathways. So-called MEK inhibitors target a protein along the same pathway as BRAF, and IGF-1 receptor inhibitors (and inhibitors of P13K, a protein that can be activated by the IGF-1 receptor pathway) block the cancer-enabling survival signal. To test these drug combinations in the BRAF-inhibitor resistant cells, the Herlyn laboratory used a tool they developed to simulate the real-world environment of human cells: 3-D melanoma tumor spheroids. Their 3-D tissue cultures allow melanoma cells to gr
'/>"/>

Contact: Greg Lester
glester@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Modern genetics vs. ancient frog-killing fungus
2. Stanford researchers: Global warming is killing frogs and salamanders in Yellowstone Park
3. Scripps research team defines new painkilling chemical pathway
4. Scientists fool bacteria into killing themselves to survive
5. Twin nanoparticle shown effective at targeting, killing breast cancer cells
6. New Southern California beetle killing oaks
7. Estrogen-dependent switch tempers killing activity of immune cells
8. Tracking new cancer-killing particles with MRI
9. Bacteria-killing proteins cover blood type blind spot
10. Killing in the name of conservation
11. Ultraviolet radiation not culprit killing amphibians, research shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Killing drug-resistant melanoma requires combination therapy
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... York December 22, 2009): Interferon gamma is a protein ... in white blood cells that cause tuberculosis. In a ... NYU Langone Medical Center have discovered that in addition to ... cells, also respond to interferon gamma and also protect mice ...
... ground too fast and you will crash and burn; too slow ... monitoring the speed of images moving across their eyes. By slowing ... the retina remains constant, bees manage to control their approach. But ... how do bees adapt to landing on surfaces ranging from the ...
... Scott & White Healthcare in Temple, Texas, found that a new ... is unique in that it works both by stopping the cancer ... the immune system to destroy breast cancer cells and keeps them ... work in both ways, while all other treatments work in one ...
Cached Biology News:Final moments of bee landing tactics revealed 2Final moments of bee landing tactics revealed 3Scott & White Healthcare researcher finds success with new anti-cancer drug 2
(Date:4/21/2015)... April 21, 2015 Ampio Pharmaceuticals, Inc. (NYSE ... investor call on Thursday, April 23, 4:30 p.m. ET. ... as follows: Investor call information: ... 789-4877 International toll number: (925) 418-7845 Participant Passcode: 32888538 ... Tina Amirkiai , tina.amirkiai@fleishman.com . ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... that Dr. Mark W. Sawicki , ... 3rd Annual BioLogistics Summit in San ...
(Date:4/21/2015)... April 21, 2015  scPharmaceuticals, Inc., a ... products for subcutaneous delivery, announced today that ... its investigational proprietary drug product, Furosemide Injection ... with congestive heart failure. Concurrently ... a proprietary patch pump.  The patch pump ...
(Date:4/21/2015)... Bruno, CA (PRWEB) April 21, 2015 ... CRO, will sponsor and exhibit at the ACRP 2015 ... Salt Lake City, Utah. The Association of Clinical Research ... annual clinical research conference solely focused on the conduct ... membership, training and development, and widely recognized industry certifications. ...
Breaking Biology Technology:Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2
... Feb. 28 InterMune, Inc.,(Nasdaq: ITMN ) ... Officer of InterMune, will present at Susquehanna,s Second ... on March 5, 2008,at 2:30 p.m. EST., ... presentation, investors and other,interested parties may log on ...
... ... Feb. 28 Cepheid (Nasdaq:,CPHD) today announced financial results for the fourth quarter and full,year ... Total revenues of $129.5 million, a 48 percent increase from $87.4 ... - Total product sales of $116.5 million, a 41 percent increase from ...
... N.C., Feb. 28 PPD, Inc. (Nasdaq:,PPDI) today ... (NDA) for alogliptin, a highly selective DPP-4 inhibitor ... accepted for filing by the U.S.,Food and Drug ... Under PPD,s agreement with Takeda, the FDA,s ...
Cached Biology Technology:InterMune to Present at the SIGnificant Options in Healthcare Conference 2Cepheid Reports Fourth Quarter and Full Year 2007 Results 2Cepheid Reports Fourth Quarter and Full Year 2007 Results 3Cepheid Reports Fourth Quarter and Full Year 2007 Results 4Cepheid Reports Fourth Quarter and Full Year 2007 Results 5Cepheid Reports Fourth Quarter and Full Year 2007 Results 6Cepheid Reports Fourth Quarter and Full Year 2007 Results 7Cepheid Reports Fourth Quarter and Full Year 2007 Results 8Cepheid Reports Fourth Quarter and Full Year 2007 Results 9Cepheid Reports Fourth Quarter and Full Year 2007 Results 10Cepheid Reports Fourth Quarter and Full Year 2007 Results 11Cepheid Reports Fourth Quarter and Full Year 2007 Results 12Cepheid Reports Fourth Quarter and Full Year 2007 Results 13Cepheid Reports Fourth Quarter and Full Year 2007 Results 14PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration 2
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
Biology Products: